OBJECTIVE: To offer guidance for psychiatric patients about rational drug use and improve patient's compliance.METHODS: Clinical pharmacists answered the questions encountered by patients during medication process by means of face-to-face talk with patients or their relatives and telephone inquiry.RESULTS: Patients' drug counseling in psychiatry department covered wide range,much as in the aspects of drug interactions and adverse drug reactions.Due to medication consultation service,patient's consciousness of rational drug use had been improved and some medication errors had been avoided,clinical pharmacists' professional knowledge has been enriched and clinical pharmacy has been enhanced and developed.CONCLUSION: The medication consultation service developed in psychiatric department is of positive practical significance in promoting rational drug use and improving clinical efficacy.

BACKGROUNDTo evaluate potential clinical roles of monoclonal antibody (MoAb)-based radioimmunotherapy in the treatment of lung cancer.

METHODSAnti-lung cancer monoclonal antibody LC-l IgM was combined with ⁹⁰Y to produce radioimmunological targeting drug. Human lung cancer tissue was inoculated subcutaneously in 35 nude mice. They were randomized into seven groups while the tumor was 5 mm in diameter. The groups were divided by the dose of the drug injected to the tail vein of the mice: blank group, LC-1 IgM alone, ⁹⁰Y 50 μCi alone, 50 μCi, 150 μCi, 300 μCi, and 400 μCi combined therapy groups. The size of the tumor was measured weekly and the mice were killed in four weeks after treatment. The tumors were resected and weighed.

RESULTSAs compared to blank group, therapy groups' tumor growth was inhibited and the inhibition was dose- and time-dependent. The inhibition rates of 300 μCi and 400 μCi groups were significantly different (P < 0.05). The nuclei of tumor cells showed karyopycnosis, structure disorder and rupture after treatment by pathological exam. In some regions, the tumor cells were necrotic or disappeared.

CONCLUSIONSThe results indicate that the radioimmunological drug made from lung cancer monoclonal antibody LC-1 IgM and ⁹⁰Y can specifically localise in tumor tissue and ensure radioimmunological targeting therapy, so has underlying clinical value.

OBJECTIVETo explore the effect and molecular mechanism of the unconventional prefoldin RPB5 interactor (URI) in hepatocellular carcinoma HepG2 cells.

METHODSThe cDNA sequence and shRNA of URI were obtained and sub-cloned into eukaryotic expression vectors. Then those vectors were transfected into HepG2 cells to obtain stable transfection cell line. The cell proliferation and anchor-independent growth in URI-overexpressing and knockdown HepG2 cells were determined by CCK-8 and soft agar colony assay. Flow cytometry was applied to detect the cell cycle and apoptosis of γ-ray irradiated cells. Apoptosis related genes were detected by Western blot.

RESULTSThe pCDNA3.1-URI and pGPU6-URIi eukaryotic expression vectors were constructed successfully and corresponding stable transfection cell lines were obtained. Cell proliferation rates of the HepG2, pCDNA3.1-URI-HepG2 and pGPU6-URIi-HepG2 cells were (588.78 ± 32.12)%, (959.33 ± 58.8)% and (393.93 ± 39.7)%, respectively (P < 0.05). The number of cell clones of HepG2, pCDNA3.1-URI-HepG2 and pGPU6-URIi-HepG2 cells were 43 ± 7, 85 ± 5 and 20 ± 4 (P < 0.05), respectively. After γ-ray irradiation, the URI-overexpressing cell line showed a significantly lower apoptosis rate and G(2)/M phase arrest than those in the URI-depleted cell line (P < 0.05). In the HepG2 cells, the relative protein expression levels of URI, Bax and Bcl-2 were 0.92 ± 0.03, 1.11 ± 0.13 and 0.82 ± 0.01 (P < 0.05). In the pCDNA3.1-URI-HepG2 cells, the relative protein expression levels of URI, Bax and Bcl-2 were 1.79 ± 0.12, 0.48 ± 0.01 and 2.20 ± 0.30 (P < 0.05), respectively. In the pGPU6-URIi-HepG2 cells, the relative protein expression levels of URI, Bax and Bcl-2 were 0.50 ± 0.04, 1.52 ± 0.20 and 0.38 ± 0.01 (P < 0.05), respectively. The expression of Bax was down-regulated and Bcl-2 was up-regulated in the URI-overexpressing cell line. However, on the contrary, expression of Bax was up-regulated and Bcl-2 was down-regulated in the URI-depleted cell line.

CONCLUSIONSURI may promote the growth of hepatocellular carcinoma cells via inhibition of cell proliferation and reducing the apoptosis in hepatocellular carcinoma cells in vitro. After the impairment of URI expression, the proliferation ability of hepatocellular carcinoma cells is suppressed and the ability to resist γ-ray irradiation is reduced. URI may become a potential new target for cancer therapy of hepatocellular carcinoma.

Apoptosis ; Carcinoma, Hepatocellular ; metabolism ; Cell Cycle ; Cell Proliferation ; Down-Regulation ; Genetic Vectors ; Hep G2 Cells ; Humans ; Intracellular Signaling Peptides and Proteins ; metabolism ; Liver Neoplasms ; RNA, Small Interfering ; Transfection

Humans ; Bacteremia ; Cross Infection ; Methicillin-Resistant Staphylococcus aureus ; Retrospective Studies ; Sepsis ; Staphylococcal Infections/epidemiology* ; Staphylococcus aureus ; Tertiary Care Centers ; China